Vikas Gupta

24.8k total citations
438 papers, 9.7k citations indexed

About

Vikas Gupta is a scholar working on Hematology, Genetics and Public Health, Environmental and Occupational Health. According to data from OpenAlex, Vikas Gupta has authored 438 papers receiving a total of 9.7k indexed citations (citations by other indexed papers that have themselves been cited), including 317 papers in Hematology, 232 papers in Genetics and 71 papers in Public Health, Environmental and Occupational Health. Recurrent topics in Vikas Gupta's work include Myeloproliferative Neoplasms: Diagnosis and Treatment (204 papers), Chronic Myeloid Leukemia Treatments (153 papers) and Acute Myeloid Leukemia Research (149 papers). Vikas Gupta is often cited by papers focused on Myeloproliferative Neoplasms: Diagnosis and Treatment (204 papers), Chronic Myeloid Leukemia Treatments (153 papers) and Acute Myeloid Leukemia Research (149 papers). Vikas Gupta collaborates with scholars based in Canada, United States and United Kingdom. Vikas Gupta's co-authors include Mark D. Minden, Jeffrey H. Lipton, Hans A. Messner, Srđan Verstovšek, Ruben A. Mesa, Joseph Brandwein, Andre C. Schuh, Martin S. Tallman, John Kuruvilla and Hillard M. Lazarus and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Vikas Gupta

416 papers receiving 9.6k citations

Peers

Countries citing papers authored by Vikas Gupta

Since Specialization

Citations

This map shows the geographic impact of Vikas Gupta's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Vikas Gupta with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Vikas Gupta more than expected).

Fields of papers citing papers by Vikas Gupta

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Vikas Gupta. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Vikas Gupta. The network helps show where Vikas Gupta may publish in the future.

Co-authorship network of co-authors of Vikas Gupta

This figure shows the co-authorship network connecting the top 25 collaborators of Vikas Gupta. A scholar is included among the top collaborators of Vikas Gupta based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Vikas Gupta. Vikas Gupta is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Tagraxofusp, a CD123-targeted therapy, for chronic myelomonocytic leukemia: final results of a phase 1/2 study 2025 ·PubMed ·Mrinal M. Patnaik, Haris Ali, Eunice S. Wang, Abdulraheem Yacoub, James M. Foran, Vikas Gupta, Gary J. Schiller, Don A. Stevens, Moshe Talpaz, Sarah Wall, Terra L. Lasho, Abhishek A. Mangaonkar, Talha Badar, Ross Lindsay, Antonio Galleu, Ira Gupta, Naveen Pemmaraju, Guillermo Garcia‐Manero	0
2	Efficacy of pacritinib in patients with myelofibrosis who have both thrombocytopenia and anemia. 2024 ·Journal of Clinical Oncology ·Pankit Vachhani, Vikas Gupta, Francesca Palandri, (unknown), Sarah Buckley, (unknown), Prithviraj Bose	0
3	Pacritinib is a potent ACVR1 inhibitor with significant anemia benefit in patients with myelofibrosis 2023 ·Blood Advances ·Stephen T. Oh, Ruben A. Mesa, Claire Harrison, Prithviraj Bose, Aaron T. Gerds, Vikas Gupta, Bart L. Scott, Jean‐Jacques Kiladjian, Alessandro Lucchesi, Tim Kong, Sarah Buckley, Shanthakumar Tyavanagimatt, Bryan Harder, (unknown), Jennifer A. Smith, Adam R. Craig, John Mascarenhas, Srđan Verstovšek	39
4	Targeted blockade of interleukin-8 negates metastasis and chemoresistance via Akt/Erk-NFκB axis in oral cancer 2023 ·Cytokine ·(unknown), Ritu Pandey, Ashok Kumar, Vikas Gupta, Neha Arya	9
5	POSTER: MPN-551 Clinical Outcomes With Momelotinib vs Ruxolitinib in Patients With Myelofibrosis and Anemia: Subgroup Analysis of SIMPLIFY-1 2023 ·Clinical Lymphoma Myeloma & Leukemia ·Vikas Gupta, Stephen T. Oh, Timothy Devos, Viviane Dubruille, John Catalano, (unknown), Pilar Giraldo, Hiroshi Kosugi, Tomasz Sacha, Jiří Mayer, Árpád Illés, Catherine Ellis, Zhaohui Wang, Jun Kawashima, Ruben A. Mesa	1
6	Evidence creation for myelofibrosis: Challenges and opportunities 2023 ·British Journal of Haematology ·Vikas Gupta	0
7	Molecular Characterization of Emerging Lumpy Skin Disease Virus in Western Uttar Pradesh, India 2023 ·(unknown), (unknown), (unknown), (unknown), (unknown), Vikas Gupta, Anu Rahal, Amit Kumar	1
8	Impact of Geographical Distance from Quaternary Treatment Center on Clinical Trial Participation, Intensive Induction Chemotherapy, and Outcomes in Patients with Newly Diagnosed Acute Myeloid Leukemia 2023 ·Acta Haematologica ·(unknown), Eshetu G. Atenafu, Steven M. Chan, Vikas Gupta, Dawn Maze, Andre C. Schuh, Hassan Sibai, Karen Yee, (unknown)	1
9	Matching-adjusted indirect comparison of the pelabresib-ruxolitinib combination vs JAKi monotherapy in myelofibrosis 2023 ·Blood Advances ·Vikas Gupta, John Mascarenhas, Marina Kremyanskaya, Raajit K. Rampal, Moshe Talpaz, Jean‐Jacques Kiladjian, Alessandro M. Vannucchi, Srđan Verstovšek, Gozde Colak, Debarshi Dey, Claire Harrison	4
10	CRP/Albumin Ratio and Glasgow Prognostic Score Provide Prognostic Information in Myelofibrosis Independently of MIPSS70—A Retrospective Study 2023 ·Cancers ·(unknown), (unknown), Thomas Volken, Sergio Cogliatti, Thomas Lehmann, Andreas Holbro, Rudolf Benz, Lukas Graf, Vikas Gupta, Wolfram Jochum, (unknown), Tata Nageswara Rao, Tobias Silzle	2
11	Momelotinib in Myelofibrosis Patients With Thrombocytopenia: Post Hoc Analysis From Three Randomized Phase 3 Trials 2023 ·HemaSphere ·Jean‐Jacques Kiladjian, Alessandro M. Vannucchi, Aaron T. Gerds, Vikas Gupta, Srđan Verstovšek, Miklós Egyed, Uwe Platzbecker, Jiřı́ Mayer, Sebastian Grosicki, Árpád Illés, (unknown), Stephen T. Oh, Donal P. McLornan, Ilya Kirgner, Sung‐Soo Yoon, Claire Harrison, Barbara Klencke, Mei Huang, Jun Kawashima, Ruben A. Mesa	10
12	Safety of re‐challenging adults with acute lymphoblastic leukemia with PEG‐asparaginase‐induced severe hypertriglyceridemia when treated with a pediatric‐inspired regimen 2022 ·SHILAP Revista de lepidopterología ·(unknown), (unknown), (unknown), Eshetu G. Atenafu, Taylor Young, Steven M. Chan, Vikas Gupta, Dawn Maze, Aaron D. Schimmer, Andre C. Schuh, Karen Yee, Hassan Sibai	2
13	Overall survival in the SIMPLIFY-1 and SIMPLIFY-2 phase 3 trials of momelotinib in patients with myelofibrosis 2022 ·Leukemia ·Ruben A. Mesa, Claire Harrison, Stephen T. Oh, Aaron T. Gerds, Vikas Gupta, John Catalano, Francisco Cervantes, Timothy Devos, Marek Hus, Jean‐Jacques Kiladjian, Ewa Lech‐Marańda, Donal P. McLornan, Alessandro M. Vannucchi, Uwe Platzbecker, Mei Huang, Bryan Strouse, Barbara Klencke, Srđan Verstovšek	40
14	The MDM2 antagonist idasanutlin in patients with polycythemia vera: results from a single-arm phase 2 study 2021 ·Blood Advances ·John Mascarenhas, Francesco Passamonti, Kate Burbury, Tarec Christoffer El‐Galaly, Aaron T. Gerds, Vikas Gupta, Brian Higgins, (unknown), Candice Jamois, Bruno Kovic, Ling‐Yuh Huw, (unknown), Margherita Maffioli, Ruben A. Mesa, Jeanne Palmer, Marta Bellini, David M. Ross, Alessandro M. Vannucchi, Abdulraheem Yacoub	16
15	Recurrent deletions in clonal hematopoiesis are driven by microhomology-mediated end joining 2021 ·Nature Communications ·(unknown), Akhiad Bercovich, (unknown), Noa Chapal-Ilani, Amanda Mitchell, Jessie J.F. Medeiros, Tamir Biezuner, Nathali Kaushansky, Mark D. Minden, Vikas Gupta, Michael Milyavsky, Zvi Livneh, Amos Tanay, Liran I. Shlush	20
16	Comparing the safety and efficacy of ruxolitinib in patients with Dynamic International Prognostic Scoring System low‐, intermediate‐1‐, intermediate‐2‐, and high‐risk myelofibrosis in JUMP, a Phase 3b, expanded‐access study 2021 ·Hematological Oncology ·Francesco Passamonti, Vikas Gupta, Bruno Martino, Lynda Foltz, Andrey Zaritskey, Haifa Kathrin Al‐Ali, Renato Tavares Daher, Margherita Maffioli, Pia Raanani, Pilar Giraldo, Martin Grießhammer, Paola Guglielmelli, (unknown), Carole Paley, Ranjan Tiwari, Alessandro M. Vannucchi	8
17	High Overall and GVHD-Free Survival in Patients with Aplastic Anemia Receiving in vivo T-cell Depletion Transplants and Long-Term Complications 2020 ·PubMed ·María Queralt Salas, Eshetu G. Atenafu, Wilson Lam, Arjun Law, Dennis Dong Hwan Kim, Fotios V. Michelis, Zeyad Al‐Shaibani, Armin Gerbitz, Jeffrey H. Lipton, Auro Viswabandya, Jonas Mattsson, Vikas Gupta, Rajat Kumar	1
18	Phase 3 Study Of Pomalidomide In Myeloproliferative Neoplasm (MPN)-Associated Myelofibrosis With RBC-Transfusion-Dependence 2013 ·Blood ·Ayalew Tefferi, Francesco Passamonti, Tiziano Barbui, Giovanni Barosi, Kebede H. Begna, Mario Cazzola, Francisco Cervantes, Konstanze Döhner, Heinz Gisslinger, Vikas Gupta, Wang Li, Claire Harrison, Jean‐Jacques Kiladjian, Mary Frances McMullin, Alessandro Rambaldi, Gary J. Schiller, Alessandro M. Vannucchi, Ruben A. Mesa	24
19	Alemtuzumab with fludarabine and cyclophosphamide reduces chronic graft-versus-host disease after allogeneic stem cell transplantation for acquired aplastic anemia 2011 ·Blood ·Judith Marsh, Vikas Gupta, ZiYi Lim, Aloysius Ho, Robin Ireland, Janet Hayden, Victoria Potter, Mickey Koh, (unknown), Nigel H. Russell, David I. Marks, Ghulam J. Mufti, Antonio Pagliuca	105
20	Effect of Age on Outcome of Reduced-Intensity Hematopoietic Cell Transplantation for Older Patients With Acute Myeloid Leukemia in First Complete Remission or With Myelodysplastic Syndrome 2010 ·Journal of Clinical Oncology ·Brian McClune, Daniel J. Weisdorf, Tanya L. Pedersen, Gisela Tunes da Silva, Martin S. Tallman, Jorge Sierra, John F. DiPersio, Armand Keating, Robert Peter Gale, Biju George, Vikas Gupta, Theresa Hahn, Luis Isola, Madan Jagasia, Hillard M. Lazarus, David I. Marks, Richard T. Maziarz, Edmund K. Waller, Christopher Bredeson, Sergio Giralt	338

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact